The international prospective Glanzmann Thrombasthenia Registry: treatment and outcomes in surgical intervention

Disclosures: MCP was chair of Novo Nordisk’s expert panel on the GTR, has been an ad hoc speaker for Bayer, Novo Nordisk and Pfizer, and attended advisory board meetings of Biogen-IDEC, CSL-Behring, Novo Nordisk, Octapharma and Pfizer, and received grant funding from CSL-Behring. Rd’O received fees or honoraria for attending advisory boards, or speaking at symposia from Baxter, Novo Nordisk, Bayer, Pfizer, Sobi and CSL Behring. RBZ has been a speaker for Sanofi-Aventis, LEO Pharma, GlaxoSmithKline, Bayer, Boehringer Ingelheim, Pfizer, Novo Nordisk, CSL Behring, MEDA, Novartis, Octapharma, Bioteq, Wyeth and AstraZeneca, and received fees from Bioteq, CSL Behring, GlaxoSmithKline, Novartis, Sanofi-Aventis and Wyeth. He is a member of the advisory boards at Novo Nordisk, Pfizer and Bayer. He received research funding from CSL Behring. NB is an employee of Larix A/S, a clinical research organization employed by Novo Nordisk. MNDDM has acted as paid lecturer or board member and received funds for researches unrelated to the present study from Pfizer, Bayer, Bioteq and Novo Nordisk in the previous 36 months. GDM has been a speaker or a member of a speakers bureau for Boehringer Ingelheim, Sanofi-Aventis, Bayer, Novo Nordisk, Pfizer, Bioteq and Grifols, and has also acted as a consultant or ad hoc speaker/consultant for Boehringer Ingelheim, Eli Lilly, Sanofi-Aventis, Bayer, CSL Behring, Novo Nordisk, Pfizer, Bioteq and Grifols.

Contributions: MCP, Rd’O, RBZ and GDM, as members of Novo Nordisk’s expert panel on Glanzmann Thrombasthenia Registry (GTR), participated in the planning and data monitoring of the GTR. All authors participated in data analysis, with NB and MNDDM providing the statistical analytical expertise. MCP wrote the initial manuscript and all authors contributed equally to the revision, finalization and approval of the manuscript.